Teva Pharmaceutical Industries (TEVA) Stock Rating Lowered by Wells Fargo & Co

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by investment analysts at Wells Fargo & Co from a “market perform” rating to an “underperform” rating in a research note issued to investors on Friday, MarketBeat.com reports. They currently have a $17.00 price target on the stock, down from their prior price target of $19.58. Wells Fargo & Co’s price objective would suggest a potential downside of 11.55% from the company’s current price.

Several other equities research analysts have also recently issued reports on TEVA. BTIG Research raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Monday, September 11th. Cantor Fitzgerald set a $17.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Monday, September 11th. Jefferies Group lowered their price objective on shares of Teva Pharmaceutical Industries from $21.00 to $18.50 and set a “hold” rating for the company in a research report on Tuesday, September 12th. Oppenheimer reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, September 11th. Finally, BidaskClub raised shares of Teva Pharmaceutical Industries from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 13th. Seven investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries has a consensus rating of “Hold” and an average price target of $21.16.

Shares of Teva Pharmaceutical Industries (TEVA) opened at $19.22 on Friday. The stock has a market cap of $19,527.52, a PE ratio of 4.44, a price-to-earnings-growth ratio of 1.36 and a beta of 0.54. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $37.94.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. San Francisco Sentry Investment Group CA bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $106,000. Bronfman E.L. Rothschild L.P. raised its stake in shares of Teva Pharmaceutical Industries by 2.6% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock worth $123,000 after acquiring an additional 94 shares in the last quarter. Penserra Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $129,000. Fieldpoint Private Securities LLC bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $171,000. Finally, Fayez Sarofim & Co. bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $204,000. Hedge funds and other institutional investors own 51.98% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries (TEVA) Stock Rating Lowered by Wells Fargo & Co” was first posted by American Market News and is the property of of American Market News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/07/teva-pharmaceutical-industries-teva-stock-rating-lowered-by-wells-fargo-co.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.